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Transporter-mediated drug-drug interactions (DDI) may induce adverse clinical events. As drugs of abuse 
(DOA) are marketed without preclinical safety studies, only very limited information about interplay with 
membrane transporters are available. Therefore, 13 DOA of various classes were tested for their in vitro affinity 
to the human breast cancer resistance protein (hBCRP), an important efflux transporter. As adenosine 5'-
triphosphate (ATP) hydrolysis is crucial for hBCRP activity, adenosine 5'-diphosphate (ADP) formation was 
measured and used as in vitro marker for hBCRP ATPase activity. ADP quantification was performed by 
hydrophilic interaction liquid chromatography coupled to high resolution tandem mass spectrometry and its 
amount in test compound incubations was compared to that in reference incubations using the hBCRP substrate 
sulfasalazine or the hBCRP inhibitor orthovanadate. If DOA caused stimulation or inhibition, further 
investigations such as Michaelis-Menten kinetic modeling or IC50 value determination were conducted. Among 
the tested DOA, seven compounds showed statistically significant hBCRP ATPase stimulation. The entactogen 
3,4-BDB and the plant alkaloid mitragynine were identified as strongest stimulators. Their affinity to the hBCRP 
ATPase was lower than that of sulfasalazine but comparable to that of rosuvastatin, another hBCRP model 
substrate. Five DOA showed statistically significant hBCRP ATPase inhibition. Determination of IC50 values 
identified the synthetic cannabinoid receptor agonists JWH-200 and WIN 55,212-2 as strongest inhibitors 
comparable to orthovanadate. The present study clearly demonstrated that tested DOA show in part high 
affinities to the hBCRP within the range of model substrates or inhibitors. Thus, there is a risk of hBCRP-
mediated DDI, which needs to be considered in clinical settings. 
 
 





































































Efflux transporters such as the human breast cancer resistance protein (hBCRP) can significantly influence 
absorption, distribution, and excretion of drugs. In analogy to its close relative P-glycoprotein (P-gp), the 
hBCRP is primarily present in sites critical for drug disposition, such as epithelia of the intestine or liver and the 
endothelium of the blood-brain barrier (International Transporter et al. 2010). Consequently, it decisively 
codetermines not only bioavailability and thus therapeutic efficacy but also drug-drug interactions (DDI), which 
can increase toxicity and encourage adverse drug reactions.  
Interactions occur if translocation of a drug is influenced by a second compound either via inhibition or 
induction of the transport protein (Muller and Fromm 2011). Significantly increased plasma concentrations of 
hBCRP substrates after oral co-administration of an hBCRP inhibitor are described (Kruijtzer et al. 2002; Wang 
et al. 2018) and clinically relevant effects are expected in case of narrow therapeutic windows and toxic 
properties. However, it is important to note that transporter-based interactions may result in concentration 
changes of the substrate in a particular tissue without affecting the plasma concentration of the substrate 
followed by local toxic effects (Endres et al. 2006). This demonstrates the complexity of identifying toxicity 
mechanisms in vivo and underlines the importance of investigations of drug-transporter interactions in early 
stages of drug development.  
As the impact of transporters on clinically relevant DDI is now generally recognized to be equal to that of 
drug metabolizing enzymes (Mao et al. 2018), new drug candidates are recommended to be routinely checked 
for interactions with the hBCRP and further transport proteins (International Transporter et al. 2010). Guidelines 
on the investigation of drug interactions were for example published by the European Medicines Agency (EMA) 
or the Food and Drug Administration (EMA 2012; FDA 2017). Unfortunately, only scarce information is 
available for interplay between the hBCRP and drugs of abuse (DOA), which are marketed without preclinical 
safety studies. hBCRP inhibition was only described for the abused alkaloid ibogaine and the plant cannabinoids 
cannabinol, cannabidiol, and delta 9-tetrahydrocannabinol (Holland et al. 2007; Tournier et al. 2010) 
demonstrating that DOA have to be considered. However, nothing is known about interactions with the so-called 
new psychoactive substances and profound toxicological risk assessment is ruled out. Sold as in part legal 
alternatives to drugs under international control with similar structures and effects, these compounds pose an 
outstanding risk as they proliferate at an unprecedented rate reaching almost 500 different substances in 2015 
(UNODC 2017).  
Therefore, the aim of the present study was to test 13 DOA with various chemical structures (Fig. 1) for 
their influence on the hBCRP. Primarily, in vitro experiments are recommended to identify potential factors 
influencing drug disposition, to elucidate potential DDI mechanisms, and to yield kinetic parameters for use in 
further studies (FDA 2017). Cell-based assays or membrane-based systems are suitable to get a first indication of 
hBCRP involvement. The latter is usually based on measurement of substrate-dependent adenosine 5'-
triphosphate (ATP) hydrolysis, as the presence of ATP is crucial for an hBCRP-mediated transport. Thanks to 
this linking between substrate transport and catalytic activity followed by release of adenosine 5'-diphosphate 
(ADP) and inorganic phosphate, the ATPase activity can be used as in vitro marker for hBCRP transport 
(Sarkadi et al. 2006). Because of its simplicity and reproducibility, the ATPase assay is one of the most widely 




































































Recently, a validated ADP quantification method based on hydrophilic interaction liquid chromatography 
coupled to high resolution tandem mass spectrometry (HILIC-HRMS/MS) was published and successfully 
applied for determination of the in vitro hBCRP ATPase activity in presence of five HIV protease inhibitors 
(Wagmann et al. 2017b). This method in combination with the presented initial hBCRP ATPase activity 
screening procedure (Fig. 2) was applied in the current study for DOA testing at three different concentrations 
(5, 50, 500 µM) to get a first impression of their ATPase stimulation or inhibition potential. Further data was 
generated and used to calculate Michaelis-Menten kinetic parameters or IC50 values in case of stimulation or 
inhibition, respectively. We also investigated a model inhibitor (orthovanadate) and two model substrates 
(sulfasalazine and rosuvastatin) to clearly demonstrate suitable experimental conditions and to compare their 
data with those elucidated for the DOA. 
 
Materials and methods 
Chemicals and enzymes 
Baculovirus-infected insect cell microsomes (Supersomes) containing complementary DNA-expressed hBCRP 
(Arg482, 5 mg protein/mL) and wild-type Supersomes without hBCRP (control membrane, 5 mg protein/mL) 
used as negative control were obtained from Corning (Amsterdam, The Netherlands). After delivery, 
Supersomes were thawed at 37 °C, aliquoted, snap-frozen in liquid nitrogen, and stored at -80 °C until use. ADP 
sodium salt, ATP magnesium salt, sulfasalazine, rosuvastatin, sodium orthovanadate, ammonium acetate, MES 
hydrate, and TRIS base were obtained from Sigma-Aldrich (Taufkirchen, Germany), formic acid (MS grade) 
from Fluka (Neu-Ulm, Germany), acetonitrile, methanol (both LC-MS grade), and all other chemicals from 
VWR (Darmstadt, Germany).  
The test compounds R,S-1-(3,4-methylenedioxyphenyl)-2-butamine (3,4-BDB) and 1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-yl-(1-naphthyl)methanone (JWH-200) were supplied by Lipomed AG 
(Arlesheim, Switzerland), R,S-2-(benzylamino)-1-(4-methylphenyl)-1-propanone (benzedrone), diclofensine, 
R,S-1-(1,3-benzodioxol-5-yl)-2-(benzylamino)-1-propanone (3,4-MDBC), and R,S-1-(2-naphthyl)-2-(1-
pyrrolidinyl)-1-pentanone (naphyrone) by LG Chemicals (Teddington, UK), R,S-1-(1,3-benzodioxol-5-yl)-2-
(methylamino)-1-butanone (butylone) HCl by www.EU-Legals.com (currently not available) before it was 
scheduled, R,S-1-(4-iodo-2,5-dimethoxyphenyl)-2-propanamine (DOI) by Sigma-Aldrich, and [(3R)-5-methyl-3-
(4-morpholinylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl](1-naphthyl)methanone (WIN 55,212) 
mesylate by Chiron AS (Trondheim, Norway). (6aS)-1,2,9,10-tetramethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinoline (glaucine) HBr was obtained from Oskar Tropitzsch (Marktredwitz, Germany), N-(1-
phenylcyclohexyl)-3-ethoxypropanamine (PCEPA) HCl was provided by the Hessisches Landeskriminalamt 
(Wiesbaden, Germany), and methyl(E)-2-[(2S,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-
octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate (mitragynine) by the Department of Forensic 
Medicine, Johannes Gutenberg University (Mainz, Germany), where it was isolated from kratom leaves obtained 
from head&nature (Regensburg, Germany) (Philipp et al. 2009). N-Allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-
2-propen-1-amine (5-MeO-DALT) was synthesized by use of established methods (Brandt et al. 2008) and 
provided by the School of Pharmacy and Biomolecular Sciences, John Moores University (Liverpool, UK).  




































































Stock solutions were prepared in bidistilled water for sodium orthovanadate (10 mM), ADP, and ATP (20 mM, 
respectively) or in methanol for sulfasalazine (0.5 mg/mL), rosuvastatin, and the test compounds (1 mg/mL, 
respectively). Stock solutions were aliquoted and stored at -20 °C until use. To ensure that the organic solvent 
content in the final incubation mixtures was not higher than 3% (Chauret et al. 1998), methanolic stock solutions 
were gently evaporated under nitrogen at 70 °C and resolved in water/methanol (8:2, v/v) in a final concentration 
of 15 mM prior to incubations. To exclude negative impacts on the analytes' concentration, their peak areas in a 
concentration of 0.5 mM diluted with acetonitrile from the methanolic stock solutions or the resolved solutions 
were compared. The MS settings were the same as described before (Helfer et al. 2015). A peak area decrease of 
30% was defined as tolerable and this criterion was fulfilled for all test compound solutions. 
HILIC-HRMS/MS apparatus 
A Thermo Fisher Scientific (TF, Dreieich, Germany) Dionex UltiMate 3000 Rapid Separation (RS) UHPLC 
system with a quaternary UltiMate 3000 RS pump and an UltiMate 3000 RS autosampler was used and 
controlled by the TF Chromeleon software version 6.80. It was coupled to a TF Q-Exactive Plus mass 
spectrometer equipped with a heated electrospray ionization II source (HESI-II). Conditions and settings were 
the same as described previously (Wagmann et al. 2017b). Briefly, gradient elution was performed on a 
Macherey-Nagel (D en, Ge man ) HILIC N cle d  c l mn (125  3 mm, 3 m) ing a e  amm ni m 
acetate (200 mM, eluent A) and acetonitrile containing 0.1% (v/v) formic acid (eluent B). The flow rate was set 
to 700 µL/min and an isocratic elution with a duration of 6 min using 65% eluent B was performed at 40 °C 
column temperature, maintained by a Dionex UltiMate 3000 RS analytical column heater. The injection volume 
for all samples was 1 µL. HESI-II conditions were: sheath gas, 60 arbitrary units (AU); auxiliary gas, 10 AU; 
spray voltage, 4.00 kV; heater temperature, 320 °C; ion transfer capillary temperature, 320 °C; and S-lens RF 
le el, 60.0. Ma  calib a i n a  d ne i   anal i  acc ding  he man fac e  ec mmenda i n  ing 
external mass calibration. ADP quantification was performed using a targeted single ion monitoring (t-SIM) and 
a subsequent data-dependent MS2 (dd-MS2) mode with an inclusion list containing the exact masses of 
negatively charged adenosine 5'-monophosphate (AMP, m/z 346.0558), ADP (m/z 426.0221), and ATP (m/z 
505.9885). The settings for the t-SIM mode were as follows: microscan, 1; resolution, 35,000; AGC target, 5e4; 
maximum IT, 100 ms; and isolation window, 4 m/z. The settings for the dd-MS2 mode were as follows: 
microscan, 1; resolution, 35,000; AGC target, 2e5; maximum IT, 100 ms; isolation window, 4 m/z; and dynamic 
exclusion, 4 s. TF Xcalibur Qual Browser 2.2 software was used for data handling. The settings for automated 
peak integration were as follows: mass tolerance, 5 ppm; peak detection algorithm, ICIS; area noise factor, 5; 
and peak noise factor, 300. GraphPad QuickCalcs (GraphPad Software, San Diego, USA) was used for outlier 
detection (http://graphpad.com/quickcalcs/grubbs1), while GraphPad Prism 5.00 software was used for statistical 
evaluation. 
Before analysis of study samples, two blank samples, six levels of calibration standards in duplicate, and 
three levels of quality control (QC) samples in duplicate were measured. ADP concentrations of calibrators and 
QC samples are given in Table 1. Blank samples only contained control membranes (0.2 mg/mL) and ATP (4 
mM), while calibrators and QC samples contained the particular ADP amount as well. Prior to analysis, they 
were diluted with acetonitrile (1:1, v/v). These samples as well as the study samples were analyzed twice and the 
mean ADP area minus mean ADP area in blank samples or blank incubations was used for quantification 




































































Initial hBCRP ATPase activity screening  
To check whether the test compounds had an influence on the hBCRP ATPase activity, four different sample 
sets consisting of three samples each were used. A simplified scheme of the hBCRP ATPase activity screening 
procedure is given in Fig. 2. Setup and incubation conditions were the same as previously described with minor 
modifications (Wagmann et al. 2017b). Briefly, sample set one contained hBCRP membrane, ATP, and one of 
the test compounds, while sample set two additionally contained sulfasalazine. Sample set three consisted of 
hBCRP membrane, ATP, and sulfasalazine, while sample set four contained orthovanadate in addition. All 
reactions were started by addition of ATP and stopped after 10 min of incubation at 37 °C by addition of 30 µL 
of ice-cold acetonitrile. The mixture was centrifuged for 2 min at 10,000×g, the supernatant transferred to an 
autosampler vial, and analyzed by HILIC-HRMS/MS. Prior to incubations, hBCRP membrane was diluted with 
TRIS-MES buffer (pH 6.8), while ATP, sulfasalazine, orthovanadate, and the test compounds were diluted with 
bidistilled water. Final concentrations were 0.2 mg/mL hBCRP, 4 mM ATP, 10 µM sulfasalazine, and 400 µM 
orthovanadate. Three different concentration levels of the test compounds were used (5, 50, and 500 µM). 
Furthermore, a blank set consisting of three samples only containing ATP and control membranes (0.2 mg/mL) 
were incubated and measured. ADP in these blank incubations was subtracted from ADP in all other sample sets. 
In addition, an interference set consisting of three samples containing hBCRP membrane, ATP, and sulfasalazine 
were incubated and the reactions were stopped with acetonitrile containing one of the test compounds in a 
concentration of 500 µM instead of pure acetonitrile. 
Finally, ADP was quantified and its formation in set three was always set to 100% and ADP formation in 
all the sample sets was compared to each other. To detect ATPase stimulation, set one was compared to set four, 
while set two was compared to set three to detect ATPase inhibition (Fig. 2). ADP formation in the interference 
set should be equal to that in set three. To decide whether detected ADP formation differences were statistically 
significant or not, a one-way ANOVA was performed followed by Dunnett's multiple comparison test (***, P < 
0.001, **, P < 0.01, *, P < 0.05) using GraphPad Prism 5.00 software. Further investigations of kinetic constants 
and/or IC50 values of the test compounds were only conducted if a significant difference of at least P < 0.01 was 
detected for a minimum of one concentration level. 
Kinetic studies 
The kinetic constants were derived from incubations with hBCRP membranes. Substrate concentrations were 
chosen to allow modeling of enzyme kinetics and were always between 0.005 and 500 µM. ATP (4 mM) was 
additionally contained in the final incubation mixtures. Incubation time and hBCRP membrane concentration 
were chosen to be in the linear range of ADP formation and final conditions given in Table 2. Blank incubations 
only contained hBCRP membrane and ATP and the ADP amount found in these incubations was subtracted from 
ADP in the other incubations. All incubations were performed in triplicate. Kinetic constants were calculated by 
ADP quantification using a calibration curve (Table 1). Enzyme kinetic constants were estimated by nonlinear 
curve fitting using GraphPad Prism 5.00 software. The Michaelis-Menten equation (Eq. (1)) was used to 
calculate apparent Km and Vmax values, where v is the initial reaction velocity, S the substrate concentration, Vmax 
the maximal reaction velocity, and Km the substrate concentration at half Vmax.  
𝑣   
 




































































Determination of IC50 values  
Inhibitors were incubated at ten different concentrations (5, 10, 20, 39, 78, 156, 313, 625, 1250, 2500 µM), with 
exception of JWH-200 and WIN 55,212-2, which could not be incubated at 2500 µM due to insufficient 
solubility. Sulfasalazine (10 µM), ATP (4 mM), and hBCRP membrane (0.2 mg/mL) were additionally 
contained in the final incubation mixtures. Control incubations without inhibitor and blank incubations were also 
prepared. Blank incubations only contained control membranes and ATP. The ADP amount found in these 
incubations was subtracted from ADP in the other incubations. All incubation conditions were the same as 
described for the initial hBCRP ATPase activity screening. All incubations were conducted in duplicate. The 
IC50 values were calculated by plotting the metabolite formation (relative to the control incubations) over the 
logarithm of the inhibitor concentration using GraphPad Prism 5.00. 
Results 
Initial hBCRP ATPase activity screening  
ADP was quantified and its formation in the different sample sets (Fig. 2) was compared. ADP formation in 
sample set three (set to 100% hBCRP ATPase activity) and the interference set were found to be not 
significantly different. Residual hBCRP ATPase activity in sample set four containing sulfasalazine and 
orthovanadate ranged always between 1 and 8%. 
Results for detection of hBCRP ATPase stimulators are given in Table 3. In total, rosuvastatin and seven 
DOA demonstrated hBCRP ATPase stimulation potential. In comparison to these incubations, rosuvastatin 
showed statistically significant higher ADP formation in all tested concentrations. The DOA butylone, DOI, 
JWH-200, and mitragynine also activated the hBCRP ATPase in all tested concentration levels, whilst 3,4-BDB 
only showed an effect in the highest concentration, WIN 55,212-2 in the lowest concentration, and diclofensine 
at the lowest and the medium concentration. However, detected stimulation by rosuvastatin or DOA was lower 
than that detected in sample set three caused by 10 µM sulfasalazine. 
Results for detection of hBCRP ATPase inhibitors are given in Table 4. In total, five DOA provided an 
hBCRP ATPase inhibition potential. In comparison to incubations with sulfasalazine alone, all of these 
compounds showed statistically significant reduction of ADP formation at their highest concentration level. Only 
JWH-200 and WIN 55,212-2 also showed an effect at medium concentration. 
Kinetic studies 
The enzyme kinetic curves of sulfasalazine and rosuvastatin are depicted in Fig. 3. Kinetic curves of 3,4-BDB 
and mitragynine are given in Fig. 4. Km and Vmax values are summarized in Table 5. 
Determination of IC50 values  
IC50 values of orthovanadate and the five DOA are given in Table 6. The determined IC50 values were between 
13 and 359 µM. Amongst the DOA, the synthetic cannabinoid receptor agonists JWH-200 and WIN 55,212-2 





































































As already mentioned, hBCRP ATPase activity is a widely-used in vitro model to get a first impression of 
interactions between test compounds and efflux transporters. As ATP hydrolysis is substrate-dependent, ATPase 
activity increases in the presence of transported substrates, while noncompetitive inhibitors reduce the ATPase 
activity of the investigated transport protein (Sarkadi et al. 2006). If ATP is hydrolyzed, inorganic phosphate and 
ADP are released. The latter can be quantified and used as in vitro marker for hBCRP ATPase activity 
(Wagmann et al. 2017b). Direct analysis of the product ADP, by use of HILIC-HRMS/MS, is less interference-
prone than colorimetric measurement of inorganic phosphate or bioluminescence-based analysis of residual ATP 
(Kaskova et al. 2016; Upreti 1984). However, drawbacks of the ATPase assay include inconsistency between 
ATPase activity and the transport rate of some substrates and inhibitors, a high incidence of false positives and 
negatives, and the requirement of high substrate concentrations (International Transporter et al. 2010). 
Nevertheless, notable advantages are simplicity, reproducibility, and particularly cost-effectiveness, as hBCRP 
expressing membrane fragments can be used, which are cheaper than membrane vesicles or cell culture 
experiments.  
To extend the knowledge surrounding interactions between DOA and the hBCRP, 13 DOA were tested 
for their influence on the hBCRP ATPase. These test compounds belonged to various DOA classes for example 
stimulants, entactogens, or synthetic cannabinoid receptor agonists and provided different chemical structures 
(Fig. 1). All of them were shown previously to be stimulators of the P-gp ATPase and/or P-gp inhibitors using 
polarized cell monolayers (Meyer et al. 2013; Meyer et al. 2015). As a broad overlap between P-gp and hBCRP 
substrates was described (Hira and Terada 2018), these compounds were now investigated for their influence on 
the hBCRP ATPase. 
The used initial hBCRP ATPase activity screening setup was already successfully applied for 
investigation of five HIV protease inhibitors. Amongst them, three were identified as hBCRP inhibitors 
(Wagmann et al. 2017b). However, none of them showed hBCRP ATPase stimulation and therefore the known 
stimulator rosuvastatin (Huang et al. 2006) was used as control. As only adenosine phosphates were analytically 
detected, it was mandatory to investigate the influence of all test compounds on the ADP MS signal. Both, 
enhancement or suppression of the ADP signal could lead to errors in assessing a compound's hBCRP substrate 
or inhibitor properties. However, no analytical interferences were detected as the ADP formation in the 
interference set and sample set three were always similar. Furthermore, sample set four provided minimal 
residual hBCRP ATPase activity what confirmed almost complete hBCRP inhibition by orthovanadate.  
The EMA defined that in case of DDI, one compound acts as victim drug and the other one as perpetrator 
drug. The victim drug is the compound affected by DDI, while the perpetrator drug is that one, which affects the 
pharmacokinetic and/or pharmacodynamic properties of the victim drug (EMA 2012). In the context of hBCRP-
mediated interactions, an hBCRP substrate would rather act as victim, while an inhibitor would be the 
perpetrator. Both possibilities should be considered and investigated and therefore hBCRP ATPase stimulators 
as well as inhibitors should be identified. 
According to the previous study, ADP formation in sample set one was initially compared to that in 
sample set three to detect hBCRP ATPase stimulators (Wagmann et al. 2017b). ADP formation in rosuvastatin 
incubations was found to be significantly lower than ADP formation in sample set three, indicating that 
rosuvastatin was either no or a weaker hBCRP substrate than sulfasalazine. However, sulfasalazine is widely 
accepted as ideal hBCRP probe substrate (Jani et al. 2009), causing intense hBCRP ATPase stimulation, which 




































































was compared to that in sample set four instead of sample set three to identify also weaker hBCRP ATPase 
stimulators than sulfasalazine. This alignment had no influence on the negative assessment of the hBCRP 
ATPase stimulation properties of the HIV protease inhibitors, which were previously reported to be no hBCRP 
substrates (Gupta et al. 2004). Even if rosuvastatin and seven DOA were shown to have hBCRP ATPase 
stimulation properties, maximum ATPase activity was always less than 50% of that caused by sulfasalazine. As 
already mentioned above, the hBCRP ATPase stimulation caused by sulfasalazine was expected to be more 
pronounced than that generated by other hBCRP substrates. The findings are in line with this assumption. As 
highest hBCRP ATPase activities were mainly caused by the medium test compound concentration (50 µM), the 
occurrence of substrate-dependent inhibition at higher concentrations is likely. 
To identify potential hBCRP ATPase inhibitors, ADP formation in sample set two was compared to that 
in sample set three. Five DOA were shown to have hBCRP ATPase inhibition potential. To reduce the hBCRP 
ATPase activity rather high concentrations of 3,4-BDB, diclofensine, or mitragynine were needed, compared to 
lower concentrations of JWH-200 or WIN 55,212-2. It is notable, that all of these inhibitory substances also 
showed stimulating properties in the initial hBCRP ATPase activity screening, what could indicate a partial 
competitive inhibition mechanism. However, in case of rosuvastatin, no inhibitory properties were detected in 
co-incubations with sulfasalazine.  
The initial hBCRP ATPase activity screening demonstrated that only selected DOA had an influence on 
the hBCRP ATPase activity. As only these substances were further investigated by kinetic studies or IC50 value 
determination, time and costs could be saved. Such prescreening procedures were already successfully applied to 
detect interactions with other enzymes (Dinger et al. 2016; Wagmann et al. 2017a).  
The Michaelis-Menten kinetics of sulfasalazine and rosuvastatin (Fig. 3) were modeled as controls to 
demonstrate that the chosen incubation conditions were suitable. Determined Km values were similar to 
published Km values for sulfasalazine (0.70 µM) (Jani et al. 2009) or rosuvastatin (10.8 µM) (Huang et al. 2006), 
respectively. Not only the Km value of sulfasalazine was lower than that of rosuvastatin but also its Vmax value 
was higher. Both parameters indicated that sulfasalazine is a stronger hBCRP substrate than rosuvastatin, as 
already assumed after the initial hBCRP ATPase activity screening. Concerning DOA, 3,4-BDB provided a Km 
value comparable to that of rosuvastatin, while the Km value of mitragynine was higher. Determined Vmax values 
of the test compounds were lower than Vmax values of the model substrates indicating a slower transport rate of 
the DOA. Although butylone, diclofensine, DOI, JWH-200, and WIN 55,212-2 showed initial activity in the 
screening studies, enzyme kinetics could finally not be modeled due to insufficient activities. 
For presumed hBCRP ATPase inhibitors, the inhibitor concentration at which the enzyme activity is 
reduced by 50% should be determined. This concentration is expressed as IC50 value. To demonstrate that 
chosen incubation conditions were suitable, the IC50 value of the model inhibitor orthovanadate was determined 
and comparable to that described in literature (20 µM) (Ishikawa et al. 2003). Additionally, IC50 values of five 
DOA were determined. To predict a potential clinical relevance of the hBCRP inhibition based on IC50 values, 
expected plasma concentrations (given in Table 6) should be considered. Unfortunately, only limited information 
concerning DOA plasma concentrations is available. Generally, case reports are the only information source and 
interpretation is difficult due to single cases, polytoxicomania, or post mortem concentrations that are affected by 
post mortem redistribution (Staeheli et al. 2017). In case of 3,4-BDB only a single post mortem concentration 
was published and in this case 2.1 mg/L amphetamine and 0.4 mg/L N-methyl-1-(3,4-methylenedioxyphenyl)-2-




































































stimulating properties but was originally developed as antidepressant (Meyer et al. 2015). Published 
concentrations were derived from a controlled experiment after intake of doses common for antidepressant 
therapy (Strojny and de Silva 1985) and are therefore not necessarily equal to doses in case of abuse. 
Mitragynine concentrations were determined in 10 chronic kratom users with the aim of investigating its 
pharmacokinetics (Trakulsrichai et al. 2015). As plasma concentrations after intake of JWH-200 or WIN 55,212-
2 have not yet been determined, those published for over 20 other synthetic cannabinoid receptor agonists such 
as JWH-018, JWH-122, or JWH-203 were used. The given concentrations derived from a trail to investigate 
JWH-018 pharmacokinetics, driving under the influence of drug cases, intoxications, or autopsies (Karinen et al. 
2015; Toennes et al. 2017). This fact and the large number of different synthetic cannabinoid receptor agonists 
explained the broad concentration ranges. In summary, expected DOA plasma concentrations were lower than 
the determined IC50 values. Therefore, a clinical effect seemed rather unlikely. However, it must be considered 
that concentrations in certain tissues are often higher than in plasma. This is for example more than likely in the 
liver, the main metabolizing organ. Thus, the occurrence of local DDI (Endres et al. 2006) followed by local 
toxicity cannot be excluded, especially not after intake of high doses. 
Conclusions 
The present study was the first to describe the influence of a broad range of new DOA on the hBCRP ATPase 
activity. A recently published ADP quantification method and the initial hBCRP ATPase activity screening 
procedure were successfully applied for DOA testing. The results demonstrated that DOA can act as hBCRP 
ATPase stimulators or inhibitors. 3,4-BDB and mitragynine were shown to have an hBCRP ATPase stimulation 
potential. Thanks to the determination of kinetic parameters, their transport is expected to be slower than that of 
the model substrates. Nevertheless, they could act as victim drug in case of co-consumption of an hBCRP 
inhibitor followed by potential (local) toxic effects. JWH-200 and WIN 55,212-2 were identified as hBCRP 
inhibitors comparably strong as the model inhibitor. Therefore, they could act as perpetrator drug, especially 
after intake of high doses. However, as in vitro studies only have a limited conclusiveness, further investigations 
are warranted to facilitate a more complete assessment. 
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Table 1 ADP concentrations of calibrators and quality control (QC) samples. 
 Calibrator QC sample 
 1 2 3 4 5 6 low medium high 
ADP conc., µM 50 100 200 300 400 500 125 250 375 
 
Table 2 Incubation time and hBCRP membrane concentration for determination of kinetic constants. 
Test compound Incubation time, min hBCRP conc., mg/mL 
3,4-BDB 30    0.4    
Mitragynine 30    0.4    
Sulfasalazine 10    0.2    
Rosuvastatin 30    0.2    
 
Table 3 Initial hBCRP ATPase activity screening results for detection of hBCRP ATPase stimulation. 
Percentage ADP formation (percentage error in brackets) represented ADP formation in incubations containing 
one of the test compounds in relation to incubations containing the hBCRP model substrate sulfasalazine (10 
µM). Significant differences in comparison to reference incubations containing sulfasalazine and the hBCRP 
model inhibitor orthovanadate (400 µM) are marked by asterisks (***, P < 0.001, **, P < 0.01, *, P < 0.05).  
 ADP formation, % 
Test compound 5 µM 50 µM 500 µM 
Rosuvastatin 30 (2) ***  41 (3) ***  34 (3) ***  
3,4-BDB 19 (13)   13 (8)   32 (3) ***  
Benzedrone 23 (3) *  16 (1)   15 (7)   
Butylone 27 (2) **  29 (3) **  34 (2) ***  
Diclofensine 31 (4) ***  26 (3) **  11 (2)   
DOI 29 (7) **  30 (6) ***  26 (2) **  
Glaucine 13 (5)   16 (7)   16 (7)   
JWH-200 16 (4) ***  29 (1) ***  17 (1) ***  
3,4-MDBC 20 (2)   21 (3) *  18 (4)   
5-MeO-DALT 13 (5)   16 (7)   16 (7)   
Mitragynine 27 (2) ***  39 (1) ***  25 (9) **  
Naphyrone 7 (2)   32 (9) *  30 (1)   
PCEPA 18 (2)   15 (3)   21 (1) *  






































































Table 4 Initial hBCRP ATPase activity screening results for detection of hBCRP ATPase inhibition. Percentage 
ADP formation (percentage error in brackets) represented ADP formation in incubations containing one of the 
test compounds in relation to incubations containing the hBCRP model substrate sulfasalazine (10 µM) and 
significant differences are marked by asterisks (***, P < 0.001, **, P < 0.01, *, P < 0.05). 
 ADP formation, % 
Test compound 5 µM 50 µM 500 µM 
Rosuvastatin 126 (21)   129 (11)   84 (1)   
3,4-BDB 95 (8)   71 (13)   36 (16) ***  
Benzedrone 96 (3)   92 (9)   73 (3) *  
Butylone 126 (3) *  107 (14)   74 (1) *  
Diclofensine 93 (12)   97 (12)   20 (3) ***  
DOI 110 (4)   105 (4)   88 (7)   
Glaucine 67 (9)   74 (21)   82 (3)   
JWH-200 78 (10)   30 (16) ***  22 (16) ***  
3,4-MDBC 103 (1)   106 (17)   112 (25)   
5-MeO-DALT 81 (17)   86 (19)   84 (2)   
Mitragynine 86 (6)   72 (11)   31 (2) ***  
Naphyrone 99 (9)   102 (7)   85 (5)   
PCEPA 74 (8)   102 (1)   77 (10)   
WIN 55,212-2 84 (4)   32 (3) ***  25 (2) ***  
 
Table 5 Km and Vmax values of tested drugs of abuse, sulfasalazine, and rosuvastatin.  
Test compound Km, µM Vmax, pmol/µg hBCRP/min 
3,4-BDB 2.3 ± 1  5.7 ± 0.5  
Mitragynine 14 ± 3  11 ± 0.6  
Sulfasalazine 0.68 ± 0.1  128 ± 6  
Rosuvastatin 1.2 ± 0.3  26 ± 1  
 
Table 6 Test compounds, reference plasma concentrations, and IC50 values (percentage error in brackets) for 
inhibition of hBCRP ATPase activity (PM: post mortem; DUID: driving under the influence of drug). 
Test compound Common plasma concentration IC50 value, µM 
 µg/L µM  
Drugs of abuse    
3,4-BDB 106 (PM)  
(Carter et al. 2000) 
0.6 143 (1) 
Diclofensine 5  
(Strojny and de Silva 1985) 
0.02 113 (1) 
JWH-200 0.1 - 28 # (DUID cases) 
0.1 - 320 # (intoxications) 
0.1 - 199 # (PM) 
(Karinen et al. 2015)  
3 - 10 #  
(Toennes et al. 2017) 
0.0003 - 0.07 # 
0.0003 - 0.8 # 
0.0003 - 0.5 # 
 
0.008 - 0.03 # 
19 (8) 
Mitragynine 19 - 105  
(Trakulsrichai et al. 2015) 
0.05 - 0.3 359 (1) 
WIN 55,212-2 0.1 - 28 # (DUID cases) 
0.1 - 320 # (intoxications) 
0.1 - 199 # (PM) 
(Karinen et al. 2015)  
3 - 10 #  
(Toennes et al. 2017) 
0.0002 - 0.07 # 
0.0002 - 0.8 # 
0.0002 - 0.5 # 
 
0.007 - 0.02 # 
15 (8) 
Known inhibitor    
Orthovanadate - - 13 (8) 





































































Legends to the figures 
 
Fig. 1 Chemical structures of the investigated drugs of abuse. 
Fig. 2 Simplified scheme of the initial hBCRP ATPase activity screening procedure. 
Fig. 3 Kinetic curves modeled after incubation of different concentrations of sulfasalazine (left: 10 min 
incubation time, in presence of 4 mM ATP and 0.2 mg/mL hBCRP, n = 3) or rosuvastatin (right: 30 min 
incubation time, in presence of 4 mM ATP and 0.2 mg/mL hBCRP, n = 3). 
Fig. 4 Kinetic curves modeled after incubation of different concentrations of 3,4-BDB (left: 30 min incubation 
time, in presence of 4 mM ATP and 0.4 mg/mL hBCRP, n = 3) or mitragynine (right: 30 min incubation time, in 
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